Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 65.5%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 5,761 shares, a decline of 65.5% from the June 30th total of 16,698 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily volume of 17,142 shares, the short-interest ratio is presently 0.3 days.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ BOLT traded up $0.10 during trading on Monday, reaching $3.93. 200 shares of the company traded hands, compared to its average volume of 25,796. The firm has a 50 day simple moving average of $4.39 and a 200-day simple moving average of $4.82. Bolt Biotherapeutics has a 52-week low of $3.75 and a 52-week high of $7.20. The stock has a market capitalization of $7.55 million, a PE ratio of -0.24 and a beta of 1.16. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million. Equities research analysts anticipate that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC grew its position in Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares during the period. Shay Capital LLC bought a new position in Bolt Biotherapeutics in the third quarter worth approximately $85,000. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth $89,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $112,000. Finally, T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $208,000. Institutional investors own 86.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bolt Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $34.67.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.